Market Overview

Oppenheimer Maintains OP Rating, $25 PT on Insulet Corporation


Oppenheimer is maintaining its $25 PT on shares of Insulet Corporation (NASDAQ: PODD) while maintaining its Outperform rating on the stock.

“We are updating our model and reiterating our Outperform rating following PODD's announcement that it will acquire Neighborhood Diabetes,” Oppenheimer writes. “Our note on 6/2 highlighted the basics of the deal. Here, we go through the model adjustments and look at some of the upside drivers.

“While the shares have reacted to the additional products brought on board for distribution through ND and their impact on gross margin, we counter that the acq. enhances PODD's core OmniPod growth opportunities and immediately benefits operating income and cash flow. There is no change to the core business outlook and we continue to expect the year-end launch of the next-generation OmniPod to be a paradigm shift for the company.”

Insulet Corporation closed Monday at $18.30.


Related Articles (PODD)

View Comments and Join the Discussion!

Posted-In: insulet corporation OppenheimerM&A Analyst Ratings

Latest Ratings

WENB of A SecuritiesMaintains23.0
NTRB of A SecuritiesUpgrades
CTVAB of A SecuritiesUpgrades
CFB of A SecuritiesUpgrades
BNRB of A SecuritiesInitiates Coverage On32.3
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at